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Fractures typically heal via endochondral and intramembranous bone formation, which together 
form a callus that achieves union and biomechanical recovery. PTHrP, a PTH receptor agonist, 
plays an important physiological role in fracture healing as an endogenous stimulator of 
endochondral and intramembranous bone formation. Abaloparatide, a novel systemically-
administered osteoanabolic PTH receptor agonist that reduces fracture risk in women with 
postmenopausal osteoporosis, has 76% homology to PTHrP, suggesting it may have potential to 
improve fracture healing. To test this hypothesis, ninety-six 12-week-old male rats underwent 
unilateral internally-stabilized closed mid-diaphyseal femoral fractures and were treated starting 
the next day with daily s.c. saline (Vehicle) or abaloparatide at 5 or 20 µg/kg/d for 4 or 6 weeks 
(16 rats/group/time point). Histomorphometry and histology analyses indicated that fracture 
calluses from the abaloparatide groups exhibited significantly greater total area, higher 
fluorescence scores indicating more newly-formed bone, and higher fracture bridging scores 
versus Vehicle controls. Callus bridging score best correlated with callus cartilage score (r=0.64) 
and fluorescence score (r=0.67) at week 4, and callus rea correlated with cartilage score 
(r=0.60) and fluorescence score (r=0.89) at week 6. By micro-CT, calluses from one or both 
abaloparatide groups had greater bone volume, bone volume fraction, bone mineral content, bone 
mineral density, and cross-sectional area at both time points versus Vehicle controls. Destructive 
bending tests indicated greater callus maximum loadand stiffness in one or both abaloparatide 
groups at both time points versus Vehicle controls. These results provide preliminary preclinical 
evidence for improved fracture healing with systemically-administered abaloparatide.  










Fracture healing is usually a robust process that resto es a broken bone’s original strength and 
geometry.1 Several endogenous factors are involved in orchestrating the multi-step process 
leading to successful fracture healing,2 including parathyroid hormone-related protein (PTHrP).3 
Throughout much of the fracture healing cascade, numerous mesenchymal cell types increase 
their expression of PTHrP, including osteoblasts engaged in intramembranous ossification and 
chondrocytes involved in endochondral ossification.4-6 PTH1R, the receptor for PTHrP and PTH, 
is also highly expressed by osteoblasts and chondrocytes during fracture healing,4 and PTH1R 
mediates the anabolic responses to locally-upregulated PTHrP expression. The genetic ablation 
of PTHrP or PTH impairs long bone fracture healing in mice,5; 7 and the systemic delivery of 
recombinant or synthetic forms of PTHrP and other PTH1R ligands, including full-length 
PTH(1-84) and its active amino-terminal fragment PTH(1-34), promotes fracture healing in 
animals.3 Systemically-administered PTH(1-34) has also been shown to favorably influence 
some aspects of fracture healing in humans.3  
Clinically, the goals of fracture healing are to restore biomechanical properties of the fractured 
bone and to facilitate the return of the affected limb or region to normal physiological function,8 
and attainment of these goals can be slow with certain fracture types and patient characteristics. 
Lower-limb long bone fractures sometimes lead to prolonged disability, and evidence indicates 
that around one third of working-age patients do not return to work within 12 months after a hip 
fracture.9 Pharmacological interventions that accelerate fractu e healing can substantially lower 
the overall costs associated with fractures by accelerating the return to work.10 Among patients 
with open long bone fractures, as many as 25% may develop delayed union or nonunion,11 which 
can cause major loss of productivity, decreased quality of life, and extensive health care 









approved for the acceleration of fracture healing or for the treatment of delayed or nonunion 
fractures.3; 15 Recombinant human bone morphogenetic protein-2 (rhBMP-2) mixed with an 
absorbable collagen sponge (ACS) is indicated for the acute treatment of tibial shaft fractures,16 
but this combination ‘device’ product is associated with several safety issues and is only 
indicated for the treatment of tibial fractures that ve accessible fracture lines.17 There remains 
an unmet need for agents that can enhance the healing of open and closed fractures, and 
systemically-administered bone anabolic agents havethe potential to fulfill some of these 
needs.18 Systemic agents can be delivered to patients with open or closed fractures, including 
fractures that are managed conservatively. Systemic agents may also have utility for treating 
fractures after definitive wound closure, which holds promise for the conservative management 
of fractures that develop signs of delayed healing.  
Based on the important role of endogenous PTHrP as a mediator of fracture healing, 
pharmaceutically-active versions of PTHrP and PTHrP analogs have been tested and shown 
capable of promoting fracture healing in animals via their systemic administration.19; 20 
Abaloparatide is a novel subcutaneously-administered PTH1R agonist with 76% amino acid 
homology to PTHrP(1-34), and its daily administration to non-fractured rats and non-human 
primates increases bone formation, bone mass, and bone strength without increasing bone 
resorption.21-25 Abaloparatide is currently approved by the U.S. Food and Drug Administration 
(FDA) as a treatment for postmenopausal osteoporosis based on its ability to reduce vertebral 
and non-vertebral fracture risk.26 Due in part to its sequence homology with PTHrP, we 
hypothesized that abaloparatide will mimic or amplify some of the chondrogenic and/or 
osteogenic effects of endogenous PTHrP during fractu e healing, potentially leading to 









osteotomy study showed that 28 days of abaloparatide dministered to mice at a single high dose 
was associated with greater callus bone volume, but callus histology was not evaluated and 
treatment effects on callus biomechanics were inconclusive due to high variability and relatively 
small sample sizes.27 The current report describes the effects of two dose levels of abaloparatide 
at two timepoints on callus histology, densitometry, and biomechanics in rats with a closed 
femoral fracture. This commonly used fracture model28 was selected based on its reliance on 
chondrogenic and osteogenic healing, and calluses were assessed at the early-to-intermediate 
healing timepoints of 4 and 6 weeks to determine whther abaloparatide accelerates 
biomechanical recovery during the period when calluses have yet to fully regain normal femur 
strength.  
Materials and Methods 
Animal care and surgery 
All animal procedures and activities were approved by and performed in an AAALAC-
accredited vivarium at PharmaLegacy Laboratories (Shanghai, China). A total of 135 male 
Sprague-Dawley rats were purchased from Vital River Laboratory Animal Technology Company 
(Beijing, China) at 8-9 weeks of age, including 96 initial study animals plus 39 spares for cases 
when the location or morphology of experimental fractures were unsatisfactory. Animals 
underwent a health inspection upon arrival and were acclimated two per cage for at least 7 days 
in clear polycarbonate plastic cages (40 by 24 by 20 cm). Acclimated animals were singly-
housed in a vivarium with a temperature range of 16-26 °C, relative humidity of 40-70%, and a 
12-h light/dark cycle. Animals had free access to standard rodent chow (Shanghai SLAC 









At approximately 12 weeks of age, rats were randomized nto 3 groups of 32 animals each using 
an algorithm that minimized between-group differences in body weight (BioBook V10.0). 
Animals were anaesthetized by isoflurane inhalation and their right hind limb shaved and 
cleaned for the creation of a closed, internally-stabilized mid-diaphyseal fracture, as described 
previously.28 Briefly, a medial peri-patellar incision was made, the patella was laterally 
displaced, and a sterile 20-gauge needle was inserted through the trochlear groove into the 
marrow cavity. The needle was removed and a sterile 1.2 mm diameter Kirschner wire (~27 mm 
long) was inserted to occupy most of the length of the medullary canal. The pinned femur was 
then positioned on a 3-point bending device and a single 700 g weight was dropped onto the 
femoral mid-diaphysis from a height of 25 cm to create a transverse fracture, which was 
confirmed by Faxitron X-ray images while the animals remained anesthetized. Buprenorphine 
HCl (0.05 mg/kg, i.m.) was administered for pain and gentamicin (20 mg/kg, i.m.) for infection 
control. Animals exhibiting improper pin placement, or unduly comminuted or poorly located 
fractures were euthanized by CO2 plus cervical dislocation or cardiac exsanguination, and 
animals from the pool of 39 spare rats underwent the fracture protocol to achieve a final n of 32 
fractured animals per treatment group. Animals were allowed to fully weight-bear after recovery 
from anesthesia. Animals were weighed at least onceper week as a health-monitoring measure 
and for weight-based treatment dosing adjustments, a d were observed daily to assess general 
health, recovery from surgery, and reactions to treatm nt.  
Treatments, radiography, and sample sizes 
One day after surgery, animals began receiving daily s.c. injections of 0.9% sodium chloride 
(Veh) or abaloparatide (Radius Health) at 5 (ABL5) or 20 µg/kg (ABL20) in a volume of 1 









over a 6-week treatment period in ovariectomized rats.21 All animals were injected s.c. with the 
fluorochrome label calcein (10 mg/kg; Sigma Aldridge) 8 and 2 days prior to sacrifice.  
Fracture site microradiographs were obtained at the start of treatment and weekly thereafter until 
necropsy for evaluations of callus formation and healing progress. Sixteen animals from each of 
the three treatment groups were sacrificed after 4 weeks and 6 weeks of treatment by CO2 plus 
cervical dislocation or cardiac exsanguination. Thenumber of animals (16 per group per time 
point) was chosen to provide 12 fracture samples for biomechanical analyses and 4 samples for 
histology.  
Sample collection and evaluation 
Fractured femurs were carefully harvested from all animals during scheduled necropsies. Twelve 
randomly-selected fractured femurs per group were wrapped in saline-soaked gauze and stored at 
-20°C prior to micro-CT and biomechanical assessment; co tralateral femurs from these animals 
were similarly stored. The remaining 4 fractured femurs per group were fixed in 10% neutral 
buffered formalin for at least 48 h and stored in 70% alcohol prior to micro-CT and processing 
for histomorphometry and histology. Intermedullary pins were carefully removed prior to micro-
CT scanning in all cases. 
Micro-CT 
Fractured femurs were scanned on a SkyScan 1176 system with the following settings: voltage 
65 kV; current 385 µA; exposure 300 ms; rotation 0.7° per step (197.40° total); with images 
reconstructed to a nominal 18 µm isotropic voxel size. The region of interest (ROI) comprised a 
350-slice area (slice thickness, 17.5 µm, 6.13mm total height) encompassing the fracture callus 









extent. The quantitative analysis of the ROI included the unthresholded parameters callus 
volumetric bone mineral content (vBMC), callus cross-sectional area (CSA), and callus regional 
volumetric bone mineral density (vBMD). In addition, a threshold of 100 was applied to 
determine total callus bone volume (BV) and bone volume fraction (BVF). In both cases, no 
delineation was made between the newly formed callus nd the original cortex. After scanning, 
all femurs were returned to their original storage conditions prior to biomechanical or histologic 
examination. 
Callus histology and histomorphometry 
After fixation, histology samples were further dehydrated via a graded alcohol series using a 
Shandon ExcelsierTM tissue processor (Thermo-Fisher, Shanghai, China), then embedded in 
methylmethacrylate (Thermo Fisher). Two ~200 µm-thick slabs of the callus and adjacent bone 
were harvested parallel to the long bone axis using a saw (EXAKT, Germany) and ground to ~50 
µm thickness using an EXAKT grinder (EXAKT). One unstained section was viewed under 
fluorescence microscopy to assess the extent of newly-formed calcein-labeled bone within the 
callus; semi-quantitative callus fluorescence scores w re generated in a blinded manner on a 
scale of 0 to 4 (0 = none; 1 = mild; 2 = moderate; 3 = moderate-to-marked; 4 = marked). The 
other section was stained with toluidine blue (pH 6.5) for light microscopy analyses, which 
included photomicrographs, blinded semi-quantitative histology assessments, and quantitative 
bone histomorphometry. Semi-quantitative bridging scores (scale of 0 to 4) were determined in a 
binary manner by evaluating the presence or absence of contiguous bony or cartilaginous 
bridging across the periosteum and endocortex. Eachof the two periosteal and endocortical 
surfaces were scored, with a maximum score of 4 indicating that all four evaluated surfaces were 









cartilage (scale of 0 to 4, as described above) within each of the two callus regions on each 
section; scores for the two regions were averaged, lea ing to a maximum possible score of 4. The 
stained sections were also used for histomorphometric assessment of total external callus area 
(including bone, cartilage, and other tissue) using OsteoMeasure Software (Osteometrics, 
Decatur, GA, USA).  
Biomechanical assessment of fractured and unfractured femurs 
After thawing, fractured and unfractured femurs were t sted in three-point bending using an 
MTS-858 Mini Bionix test system. Femurs underwent bending to failure at a displacement rate 
of 6 mm per minute with span length of 1 cm. Load an displacement data were used to 
determine maximum load and stiffness for each sample. 
Statistics 
One-way ANOVA was used to evaluate differences among the groups at each time point. If the 
ANOVA test was significant, Dunnett’s post-test was applied to compare the ABL5 and ABL20 
groups to Veh controls within each time point. For the qualitative callus fluorescence and 
cartilage scores, the non-parametric Kruskal-Wallis test was used to compare overall group 
differences at each time point, followed by Dunn’s multiple comparison test of each ABL group 
vs Veh control if Kruskal-Wallis was significant. These analyses and linear regressions were 












Radiographs of the fractured femur were obtained from anaesthetized animals at the time of 
fracture (week 0) and once-weekly thereafter. Representative radiographs taken at weeks 0, 2, 4, 
and 6 from the 6-week arm of the study are shown in Fig. 1. In all three groups, substantial callus 
development was evident by week 2, with an apparent increase in callus density at week 4. 
Calluses appear to be denser in the ABL5 and ABL20 groups compared with Veh controls at 
weeks 4 and 6.  
Callus Histology and Histomorphometry 
Representative photomicrographs of undecalcified toluidine blue-stained histology sections of 
week 4 and week 6 fracture calluses are presented i Fig. 2, and the following interpretations are 
consistent with observations for the overall histology sample set. At week 4, all three groups 
show substantial external callus development in the form of new intramembranous bone along 
the upper and lower periosteal surfaces; smaller and v riable degrees of internal callus 
development are evident in the form of new intramedullary bone. The week 4 abaloparatide 
examples (Fig. 2B-C) exhibit somewhat denser and more developed external calluses compared 
with Veh controls (Fig. 2A), with an apparently great r extent of purple-stained callus cartilage. 
At week 6, the abaloparatide groups (Fig. 2E-F) continue to exhibit greater amounts of new 
external and internal bony callus tissue compared with Veh controls (Fig. 2D). Callus cartilage is 
minimally evident in the Week 6 Veh and ABL5 examples, whereas the Week 6 ABL20 example 
exhibits moderate callus cartilage surrounded by external bony callus tissue. 
Histomorphometry analyses indicated that total callus area was significantly greater in both 
abaloparatide groups at week 4 and in the ABL20 group at week 6 compared with Veh controls 









scores at week 4 for the ABL20 group compared with Ve controls (p = 0.08; Fig. 3B). Callus 
fluorescence scores reflecting the extent of newly-formed bone were significantly higher in the 
ABL20 group at both time points compared with Veh controls (Fig. 3C). Callus bridging scores, 
reflecting cartilaginous and/or bony bridging across the fracture line, were significantly greater 
in both abaloparatide groups at week 4 compared with Veh controls, with similar levels of 
bridging for each group at week 6 (Fig. 3D).  
Linear regression analyses were performed to evaluate histological determinants of bridging 
scores and callus area (Table 1). Bridging score was positively related to cartilage score and 
fluorescence score at week 4 (r = 0.64 and 0.67, respectively; both P < 0.05) but not at week 6. 
Callus area at week 4 was positively related to flurescence score (r = 0.90; P < 0.0001), and 
callus area at week 6 was positively related to flurescence score (r = 0.89) and to cartilage score 
(r = 0.60; P < 0.05). 
Callus micro-CT 
Quantitative micro-CT analyses of fractured femurs indicated that the ABL5 and ABL20 groups 
had significantly greater callus bone volume, BVF, and vBMC at both time points compared 
with Veh controls (Fig. 4A-C). The ABL5 group showed significantly greater average callus 
CSA at weeks 4 and 6 compared with Veh controls (Fig. 4D). Callus region vBMD was 
significantly greater in both abaloparatide groups at both time points compared with Veh 
controls (Fig. 4E). Representative 2-D reconstructed images are shown in Fig. 5. 
Biomechanics of the callus and unfractured femur  
Destructive 3-point bending tests of fracture calluses indicated significantly greater strength 









their respective Veh control groups (Fig. 6A). Callus stiffness was significantly greater for the 
ABL5 and ABL20 groups compared with Veh controls at week 4, and for the ABL5 group 
versus Veh at week 6 (Fig. 6B). Unfractured contrala eral femurs were also subjected to 
destructive 3-point bending tests, which indicated significantly greater maximum load in the 
ABL20 group compared with Veh controls at week 4 (Fig. 6C). Stiffness values for intact femurs 
were similar across the three groups at weeks 4 and 6 (Fig. 6D). 
The degree of biomechanical recovery of fractured femurs was assessed by calculating callus 
maximum load and stiffness values for each animal as percentage of the average values for 
normal femurs (i.e., unfractured femurs from Veh contr ls). Calluses from the Veh group 
reached 24.0 ± 1.7% (mean ± SEM) and 7.4 ± 0.8% of normal maximum load and stiffness at 
week 4 (respectively), and at week 6 these values reached 35.0 ± 3.4% and 25.4 ± 3.9%, 
respectively. Calluses from the ABL5 group achieved 33.9 ± 3.8% and 11.8 ± 0.9% of normal 
maximum load and stiffness at week 4 (respectively), and at week 6 these values reached 49.2 ± 
4.6% and 53.9 ± 7.7%, respectively (all P < 0.05 vs Veh except for week 4 maximum load). 
Calluses from the ABL20 group achieved 42.5 ± 4.0% and 14.5 ± 1.0% of normal maximum 
load and stiffness at week 4, respectively (both P < 0.05 versus Veh). Maximum load remained 
similar at week 6 in the ABL20 group (42.0 ± 4.7% of n rmal) compared with week 4, whereas 
stiffness was further increased at week 6 to 30.6 ± 6.4% of normal (P < 0.05 vs. Veh). 
Micro-CT-based morphological determinants of callus biomechanics  
Determinants of callus biomechanics were assessed across the 3 groups at each time point via 
linear regression analyses of micro-CT-derived callus morphology variables versus callus 









correlated with maximum load and stiffness at week 4, with r values ranging from 0.64 to 0.81 
(all P < 0.05; Table 1). At week 4, callus region vBMD was positively associated with stiffness 
but not with maximum load (r = 0.68; P < 0.05). At week 6, callus vBMC, vBMD, and BVF 
remained positively correlated with maximum load anstiffness (r values ranging from 0.34 to 
0.76; all P < 0.05), whereas callus CSA and bone volume were no longer associated with 
maximum load or stiffness.  
Discussion 
This study provides preliminary evidence for accelerated fracture healing in animals treated with 
abaloparatide, a novel and selective PTH1R agonist with 76% homology to PTHrP. Previous 
animal studies show that genetic PTHrP deficiency reduces fracture callus chondrogenesis and 
bony callus development,29 and that exogenous PTHrP and PTHrP analogs enhance fr cture 
healing and osteotomy healing.19; 20 A recent study in mice with closed femoral fractures also 
showed that 28 days of abaloparatide administration at a single high dose (60 µg/kg/d) led to 
significantly greater callus bone volume.27 The current study shows that abaloparatide enhanced 
callus development, osteogenesis, fracture bridging, a d biomechanical recovery during the early 
and middle stages of fracture healing in rats with a closed femoral fracture. These findings 
provide further preclinical evidence that abaloparatide may improve the healing of traumatic 
fractures, and perhaps fragility fractures as well.  
Abaloparatide-treated rats exhibited larger calluses containing substantial amounts of cartilage, 
more bone, and enhanced bridging at week 4 compared with vehicle controls. These differences 
were accompanied by enhanced callus strength and stiffne s, with some evidence for accelerated 









4 than in Veh controls at week 6. Abaloparatide appe red to enhance intramembranous bone 
formation emanating from periosteal surfaces adjacent to the fracture line, an effect that could 
potentially contribute to a more extensive rigid scaffold for subsequent bridging. Bridging is 
typically achieved in this model via the formation f callus cartilage between the banks of this 
new intramembranous bone, and the abaloparatide-treated rats exhibited trends toward increased 
callus cartilage, though statistical power was limited by the small number of histology samples. 
Positive correlations between callus cartilage and bri ging scores suggest a possible contribution 
of chondrogenesis in fracture union.  
In addition to its role in initial union, callus cartilage provides a template for subsequent 
endochondral-based bone formation that provides much of the biomechanical stability of the 
healing fracture.3 The current study provides evidence for the timely conversion of callus 
cartilage to bone in all three groups, based on numerical reductions in cartilage scores between 
weeks 4 and 6 and accompanying increases in callus bone volume, vBMD, and vBMC. One or 
both abaloparatide groups also exhibited greater callus fluorescence scores, callus bone volume, 
and callus bone mineral content compared with Veh, which reflect the combined contributions of 
intramembranous and endochondral bone formation. Callus fluorescence scores correlated 
positively with total callus volume and with bridgin  scores, suggesting significant contributions 
of abaloparatide-induced osteogenesis toward bony callus development and bridging. However, 
it is important to note that improved bridging in the abaloparatide groups was seen only at week 
4 and not at week 6, despite the fact that none of the groups had achieved complete bridging at 
week 6.  
Consistent with the lack of complete bridging, destructive biomechanical testing of fracture 









stiffness of normal unfractured femurs by week 6. This degree of biomechanical recovery is 
similar to day 40 findings from another closed long-bone fracture study in rats,30 and indicates an 
early-to-intermediate stage of healing. There are advantages to evaluating treatment effects on 
callus development at these stages, including mechanistic insights gained by evaluating callus 
cartilage before and after it begins converting into bone. There is also value in assessing callus 
biomechanics at these stages, because over longer treatment periods, callus strength can 
significantly exceed the strength of normal unfractured bone, which had debatable clinical 
value.3 The current study showed that the one or both abaloparatide groups had greater callus 
strength and stiffness at weeks 4 and 6 vs Veh controls, with levels reaching up to around 50% of 
those observed for normal intact femurs. Future studies with longer follow-up periods may 
address whether abaloparatide reduces the time to achieve full callus biomechanical recovery.  
Significant positive correlations were observed betwe n several micro-CT-based callus structural 
parameters versus callus strength and stiffness. For some structural parameters (e.g., CSA and 
bone volume), relationships with callus biomechanics were evident at week 4 but not at week 6. 
This temporal shift may reflect the effects of callus remodeling, which reduces external callus 
size as internal repair processes progressively stabilize the healing fracture from within. 
Conversely, callus bone volume fraction and vBMD were better callus strength surrogates at 
week 6 than at week 4. These collective findings, and the histology-based regression analyses, 
suggest that callus cartilage, bone formation, and overall callus size and mass were the main 
determinants of early callus stability, with callus remodeling and maturity becoming more 
biomechanically relevant during the intermediate stages of healing.  
The effects of abaloparatide on bone healing in this rat study are consistent with previous 









mice and rabbits with fractures or other skeletal injur es.19; 20; 27; 31; 32 This study also has several 
limitations. A standard closed femoral fracture model was considered suitable for this initial 
abaloparatide study, but data from higher-hurdle fracture models would better inform the 
potential of abaloparatide as a possible treatment for fractures that do not readily heal on their 
own. The effects of abaloparatide were only assessed in male rats, and we cannot rule out that 
abaloparatide may have different effects on fracture healing in female rats. Cartilage scores were 
semi-quantitative and were based on Toluidine Blue-stained sections and should therefore be 
considered a preliminary assessment, pending quantitative analyses using stains that are more 
specific for cartilage matrix. The study lacked an active comparator group such as PTH(1-34) or 
BMP-2 therapy, and while neither of those therapies ar  approved for the treatment of closed 
long-bone fractures, it would nevertheless be interesting to compare their effects versus those of 
abaloparatide. Abaloparatide administration influenced unfractured bones as well, as shown by 
improved biomechanical properties of unfractured femurs. This effect was not unexpected and 
may be considered favorable in settings of low bone mass and strength, but such effects may be 
less desirable in patients who are not at increased ri k of fragility fractures. It is assumed but 
unproven that effects on unfractured bones would gra ually reverse after a completing a course 
of abaloparatide therapy for fracture healing.  
In summary, abaloparatide administration to rats wih a closed femoral fracture was associated 
with early increases in callus osteogenesis, improved fracture bridging, greater bony callus size 
and density, and improved biomechanical stability. We hypothesize that callus cartilage may 
have contributed to improved early bridging and callus stability in the abaloparatide groups, and 
that the timely conversion of this cartilage into bone, combined with abaloparatide-induced 









increased callus strength and stiffness. From a clinical perspective, early improvements in 
fracture callus stability may allow earlier recovery of physical activities including weight-
bearing, potentially leading to further improvements i  fracture healing due to an early regain of 
mechanical loading. These current findings, and those from other experimental orthopedic 
models,27 provide initial preclinical support for further studies of abaloparatide as an 
investigational agent for the promotion of bone healing.  
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Table 1: Callus morphology variables as determinants of callus bridging, area, strength 
(maximum load), and stiffness as determined by linear r gression analyses. All listed r values are 
statistically significant (P < 0.05); NS, not significant.  
Correlation coefficients (r values)  
 
Week 4 Week 6 
Callus histology and histomorphometry (n = 4/group)   
Cartilage score vs bridging score 0.64 NS 
Cartilage score vs callus area NS 0.60 
Fluorescence score vs bridging score 0.67 NS 
Fluorescence score vs callus area  0.90 0.89 
Callus micro-CT and biomechanics (n = 12/group)   
CSA vs max load 0.78 NS 
CSA vs stiffness 0.64 NS 
vBMC vs max load 0.69 0.35 
vBMC vs stiffness 0.78 0.34 
Bone volume vs max load 0.75 NS 
Bone volume vs stiffness 0.81 NS 
BVF vs max load NS 0.53 
BVF vs stiffness 0.64 0.76 
vBMD vs max load NS 0.54 
vBMD vs stiffness 0.39 0.78 
vBMC, volumetric bone mineral content; CSA, cross-sectional area; BVF, bone volume fraction; 











Figure 1: Representative radiographs of fracture calluses from the 6-week arm of the study. 
Examples were selected based on callus strength (maximum load) and stiffness values that were 
closest to their group means. Callus density in the ABL5 and ABL20 groups appears to be 
greater at week 4 and week 6 compared with Veh controls.  
Figure 2: Representative histology of undecalcified toluidine blue-stained sections of fracture 
calluses. Examples were selected based on microCT-based callus bone volume values closest to 
their group means. The red dashed line in Fig. A indicates periosteal new bone formation that 
comprises much of the external callus, and the blue arrows indicate new endocortical bone 
formation that comprises the internal callus. The purple arrows in Figs. B and C highlight callus 
cartilage within the fracture gap between the external bony callus regions.  
Figure 3: Histomorphometry- and histology-based callus analyses. A: Histomorphometry-based 
total callus area. B-D: Semi-quantitative histology-based analyses of (B) callus cartilage score, 
(C) callus fluorescence score, which reflects the ext nt of new bone formation within the 
external callus region; and (D) callus bridging score, which reflects contiguous cartilaginous and 
bony tissue that bridges the fractured ends. Data represent means and SEM, N = 4/group. *P < 
0.05 vs Veh control group at the corresponding time point. 
Figure 4: Fracture callus morphology by micro-CT. A) Callus bone volume; B) Callus bone 
volume fraction (% total volume); C) Callus volumetric bone mineral content (vBMC); D) 
Callus cross-sectional area (CSA); E) Callus region v lumetric BMD (vBMD). Data represent 
means and SEM, n = 16/group. *P < 0.05 compared with Veh at the corresponding timepoint. 
Figure 5: Representative micro-CT images of fracture calluses. S lection of these 2-D 
reconstructed images was based on samples with ultimate load values closest to their group 
means.  
Figure 6: Biomechanics results for (A, B) fracture calluses and (C, D) unfractured intact 
contralateral femurs. Data represent means and SEM, n = 12/group. *P < 0.05 vs. Veh controls at 
























































Figure 6 Biomechanics  . 
 
